Emily joined NEA in 2020 as an investor on the healthcare team working across the digital health and life sciences sectors. Emily is a Board Observer for Spiras Health, Slope, and Senti Bio, and is also involved in NEA’s investments in Vori Health, Strive Health, Waymark, Curana Health, ChromaCode, Vistagen Therapeutics, and Geron. Prior to joining NEA, Emily worked in healthcare investment banking at Goldman Sachs in New York City. She has also worked at the U.S. Department of Treasury, PwC, and early-stage digital health startups Healthie and NeuroFlow.
Emily graduated summa cum laude from the University of Pennsylvania’s Vagelos Program in Life Sciences & Management, where she earned a B.S. in Finance from Wharton, a B.A. in Biology, and a certificate in healthcare policy as a Public Policy Research Scholar. During her time at Penn, Emily engaged in research on Castleman Disease with Dr. David Fajgenbaum, served as a project leader for 180 Degrees Consulting, and conducted due diligence on healthcare startups as part of the Wharton Impact Investing Partners health & wellness team.